# Antinuclear antibodies in patients with chronic fatigue syndrome

## Citation

Nishikai M. Antinuclear antibodies in patients with chronic fatigue syndrome. Nihon Rinsho. 2007;65(6):1067-1070. PMID: 17561698

**Note:** The original search was for Nishikai 1996 in Clinical Rheumatology, but the most relevant comprehensive publication appears to be this 2007 review article. Nishikai has published multiple papers on this topic:
- Nishikai & Kosaka (1997): Incidence of antinuclear antibodies. Arthritis & Rheumatism 40:2095-2096
- Nishikai et al. (2001): Autoantibodies to 68/48 kDa protein. Rheumatology 40(7):806-810
- Nishikai (2007): This review article summarizing findings

## Key Information

- **Publication Date:** June 2007
- **Journal:** Nihon Rinsho (Japanese Journal of Clinical Medicine)
- **PMID:** 17561698
- **Study Type:** Review article
- **Language:** Japanese (abstract available in English)

## Access

- PubMed: https://pubmed.ncbi.nlm.nih.gov/17561698/

## Author

- Masanori Nishikai (prominent researcher in CFS autoimmunity)

## Key Findings from Nishikai's Research Program

**ANA Prevalence:**
- 15-25% of CFS patients test positive for antinuclear antibodies (ANA)
- Using indirect immunofluorescence with HEp-2 cells as substrates
- ANA titers are generally low
- Immunofluorescent staining patterns are heterogeneous

**Nuclear Envelope Antibodies:**
- One US group reported 'nuclear envelope staining pattern' in >50% of CFS patients
- These findings have not been confirmed by other research groups
- Remains controversial

**Specific Autoantibodies (from 2001 study):**
- Autoantibodies to 68/48 kDa protein found in:
  - 13.2% of CFS patients
  - 15.6% of fibromyalgia patients
  - 0% of healthy controls (p < 0.05)
- Associated with hypersomnia and difficulty concentrating
- More common in patients with these cognitive symptoms

## Significance

Nishikai's work was among the **first systematic investigations** of autoantibodies in CFS, establishing that a subset of patients (15-25%) have detectable autoimmune markers, though their pathogenic role remains unclear.
